Drug Combination on Exercise Performance at High Altitude
NCT ID: NCT01902758
Last Updated: 2016-02-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
28 participants
INTERVENTIONAL
2013-08-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Breathing Training to Improve Human Performance at High Altitude
NCT03530163
Training in Hypoxia to Prevent Acute Mountain Sickness
NCT00886912
Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance
NCT05575180
Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance
NCT03743610
Effects of High-Intensity Interval Training (HIT) While in a Hyperoxic-Hyperbaric Environment on Exercise Performance
NCT02941939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ambrisentan and theophylline
ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
ambrisentan and theophylline
placebo
matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
placebo
placebo for comparison group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ambrisentan and theophylline
placebo
placebo for comparison group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* currently taking any medication
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Montana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brent Ruby
Director of the Montana Center for Work Physiology and Exercise Metabolism
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montana Center for Work Physiology and Exercise Metabolism
Missoula, Montana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N66001-10-C-2134
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
UM82-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.